Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer ponders consumer unit
February 13, 2006
| A version of this story appeared in
Volume 84, Issue 7
Pfizer says it is exploring strategic alternatives for its consumer health care business, including retaining, spinning off, or selling the unit. The business includes such well-known products as Sudafed decongestant, Listerine antiseptic, and Dramamine for motion sickness. Pfizer says the objective of the review is to unlock the value of the business for its shareholders "at a time when market valuations are attractive for large, high-quality consumer businesses." The unit had sales in 2005 of $3.88 billion, up 13% from 2004.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X